



446.016-DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: :
A. PEYMAN et al :
Serial No.: 10/808,496 : Group: 1624
Filed: March 24, 2004 :
For: NAPHTHYRIDINE...THEM :

475 Park Avenue South
New York, N.Y. 10016
July 13, 2004


REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SIR:

Applicants are returning herewith the filing receipt for the above application and request that the Patent Office issue a corrected filing receipt to show that the third inventor's last name is GADEK and not Gadex.


Respectfully submitted,
Muserlian, Lucas and Mercanti




Charles A. Muserlian, 19,683
Attorney for Applicants
Tel.# (212) 661-8000

CAM:ds
Enclosures

EV 53058299745

"Express Mail" mailing label No. 112413104
Date of Deposit 7/13/04
I hereby certify that this paper or fee is
being deposited with the United States Postal
Service "Express Mail Post Office to Addressee"
service under 27 CFR 1.10 on the date indicated
above and is addressed to the Commissioner for
Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


7/13/04



7-14-04

Page 1 of 2

JFW

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/808,496	03/24/2004	1624	770	146.1377 446.016-DIV		8	1

Charles A. Muserlian
c/o Muserlian, Lucas and Mercanti
475 Park Avenue South
New York, NY 10016

RECEIVED
JUN 28 2004

CONFIRMATION NO. 5709

UPDATED FILING RECEIPT



OC000000013073614

Date Mailed: 06/25/2004

MUSERLIAN, LUCAS AND MERCANTI LLP

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Anuschirvan Peyman, Kelkheim, GERMANY;
Karl-Heinz Scheunemann, Liederbach, GERMANY;
Thomas R. Gadex, Oakland, CA;
Jean-Francois Gourvest, Claye Souilly, FRANCE;
Jean-Marie Ruxer, Issy les Moulineaux, FRANCE;

Assignment For Published Patent Application

Aventis Pharma Deutschland GmbH;
Genentech Inc.;

Domestic Priority data as claimed by applicant

This application is a DIV of 10/030,301 03/20/2002 PAT 6,743,800 *
which is a 371 of PCT/EP00/05920 06/26/2000
(*)Data provided by applicant is not consistent with PTO records.

Foreign Applications

EUROPEAN PATENT OFFICE (EPO) 99112636.8 07/02/1999

If Required, Foreign Filing License Granted: 06/07/2004

Projected Publication Date: 10/07/2004

Non-Publication Request: No

Early Publication Request: No

Title

Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).